Filter Results:
(1,246)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- Article
A Blueprint for Pharmacy Benefits Managers to Increase Value
By: William Shrank, Michael E. Porter, Sachin H. Jain and Niteesh K. Choudhary
Pharmacy benefits managers (PBMs) have a unique opportunity to promote public health and generate value in the healthcare system. However, PBMs are largely evaluated on their ability to control costs rather than improve health. PBMs should be evaluated along three... View Details
Keywords: Opportunities; Health; System; Cost Management; Partners and Partnerships; Motivation and Incentives; Value; Innovation and Invention; Performance Effectiveness; Pharmaceutical Industry; Pharmaceutical Industry
Shrank, William, Michael E. Porter, Sachin H. Jain, and Niteesh K. Choudhary. "A Blueprint for Pharmacy Benefits Managers to Increase Value." American Journal of Managed Care 15, no. 2 (February 2009).
- April 1989
- Supplement
Novel Combination of Two Drugs (C)
Herzlinger, Regina E. "Novel Combination of Two Drugs (C)." Harvard Business School Supplement 189-170, April 1989.
- April 1989
- Supplement
Novel Combination of Two Drugs (B)
Herzlinger, Regina E. "Novel Combination of Two Drugs (B)." Harvard Business School Supplement 189-169, April 1989.
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- January 1999
- Background Note
Note on the Drugstore Industry
By: David E. Bell and Ann Leamon
In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 10 Aug 2020
- Research & Ideas
COVID's Surprising Toll on Careers of Women Scientists
COVID-19 is claiming an unexpected career toll among scientific researchers, and particularly on women, new research shows. If you are female, have young children, or work in a lab, you are more likely to feel the career-crunching effects dealt by the pandemic,... View Details
- 28 Feb 2019
- Cold Call Podcast
Pursuing Precision Medicine at Intermountain Healthcare
- Web
Staff Directory | Baker Library
pharmaceutical companies, health care, travel, and personal finance. Avery holds a master’s degree from Columbia Journalism School, a Fulbright Fellowship to Russia, and a bachelor’s degree in history and international relations from... View Details
- 01 Jun 2000
- News
The Business of Biotech
business and commercial development at Millennium Pharmaceuticals in Cambridge, Massachusetts. "It will revolutionize how medicine is practiced," he states simply. "Right now the doctor listens to your heart with a stethoscope and maybe... View Details
Keywords: Julia Hanna
- 01 Sep 2012
- News
A Silent Workplace Crisis
pharmaceuticals, the gap between the medical and the mental health systems, and the time required to find community resources and quality home care. My previous experience as a pharmaceutical executive and management consultant seemed... View Details
- 01 Jun 2000
- News
The Right Connections
prospectuses of all public biotech firms going back twenty years. Information from 295 companies and more than 3,000 executives formed the core of their study. The results showed that top managers' ties to notable pharmaceutical companies... View Details
Keywords: Judith A. Ross
- 01 Mar 2005
- News
Facing Ambiguity
successfully executed in a paper case.” The case, which will be taught this spring in the MBA second-year course General Management: Processes and Action, debuted last fall in a customized Executive Education program for a group of View Details
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)